Clinical trial · Observational
Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population
Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis-A Ten Year Retrospective Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is: • Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic dosing after 6-month treatment of anticoagulant? The medical record data of participants who's already received for at least 6-month anticoagulant treatment upon regular medical care for CAT will be collected and analyzed about their recurrent thrombosis, anticoagulant related bleeding, and survival outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer-associated Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anticoagulant | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Therapeutic dose anticoagulant group
- description
- including patients with the standard therapeutic dose-administered after the initial six-month treatment period.
- interventionNames
- Drug: Anticoagulant
- label
- Prophylactic dose anticoagulant group
- description
- including patients with the doses lower than therapeutic dose-administered at any point after the initial six-month treatment period.
- interventionNames
- Drug: Anticoagulant
Primary outcomes (1)
- measure
- Recurrent thrombosis
- timeFrame
- After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Here's a polished version of your Inclusion and Exclusion Criteria section with grammar, spelling, and phrasing corrected for clarity and formal research style: Inclusion Criteria * Adult patients aged ≥18 years * Histopathologically confirmed cancer * Radiologically confirmed diagnosis of cancer-associated thrombosis (CAT) * Received anticoagulation therapy for at least six months Exclusion Criteria * Patients who do not meet the inclusion criteria
References
Publications (0)
Data not yet available